• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.

作者信息

Todberg Tanja, Skov Lone, Simonsen Stine, Kainu Kati, Zachariae Claus

机构信息

Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark.

出版信息

Acta Derm Venereol. 2020 Apr 21;100(8):adv00118. doi: 10.2340/00015555-3461.

DOI:10.2340/00015555-3461
PMID:32189005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9128897/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78a1/9128897/192a9845ce03/ActaDV-100-8-5720-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78a1/9128897/192a9845ce03/ActaDV-100-8-5720-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78a1/9128897/192a9845ce03/ActaDV-100-8-5720-g001.jpg

相似文献

1
Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.阿普米拉斯治疗结节性痒疹患者的疗效：一项概念验证研究。
Acta Derm Venereol. 2020 Apr 21;100(8):adv00118. doi: 10.2340/00015555-3461.
2
Treatment of refractory prurigo nodularis with lenalidomide.来那度胺治疗难治性结节性痒疹
Arch Dermatol. 2012 Jul;148(7):794-6. doi: 10.1001/archdermatol.2011.2918.
3
Use of lenalidomide in treating refractory prurigo nodularis.来那度胺在治疗难治性结节性痒疹中的应用。
J Drugs Dermatol. 2013 Mar;12(3):360-1.
4
Treatment of prurigo nodularis with lenalidomide.来那度胺治疗结节性痒疹
Dermatol Ther. 2017 Mar;30(2). doi: 10.1111/dth.12451. Epub 2016 Nov 28.
5
Aspirin and loxoprofen relieve refractory pruritus in patients with prurigo nodularis.阿司匹林和洛索洛芬可缓解结节性痒疹患者的难治性瘙痒。
J Dermatol. 2016 Sep;43(9):1104-5. doi: 10.1111/1346-8138.13349. Epub 2016 Mar 11.
6
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.沙利度胺治疗人类免疫缺陷病毒感染患者的结节性痒疹：疗效及神经病变风险
Arch Dermatol. 2004 Jul;140(7):845-9. doi: 10.1001/archderm.140.7.845.
7
In vivo measurements of iron, copper and zinc in the skin of prurigo nodularis patients treated with thalidomide.使用沙利度胺治疗的结节性痒疹患者皮肤中铁、铜和锌的体内测量。
Dermatologica. 1981;162(2):86-90. doi: 10.1159/000250254.
8
Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.P物质及其受体神经激肽1在慢性痒疹中的作用：一项使用阿瑞匹坦局部给药的随机、概念验证性对照试验
Acta Derm Venereol. 2018 Jan 12;98(1):26-31. doi: 10.2340/00015555-2780.
9
Treatment of prurigo nodularis with thalidomide.沙利度胺治疗结节性痒疹
Arch Dermatol. 1980 May;116(5):571-2. doi: 10.1001/archderm.116.5.571.
10
Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.低剂量沙利度胺治疗台湾特发性结节性瘙痒症患者
J Dermatol. 2007 Apr;34(4):237-42. doi: 10.1111/j.1346-8138.2007.00260.x.

引用本文的文献

1
Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.阿普司特治疗免疫介导的炎症性皮肤病：一项叙述性综述。
Front Pharmacol. 2025 Aug 21;16:1633426. doi: 10.3389/fphar.2025.1633426. eCollection 2025.
2
Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment.慢性结节性瘙痒症：发病机制和治疗的最新进展。
Int J Mol Sci. 2022 Oct 16;23(20):12390. doi: 10.3390/ijms232012390.

本文引用的文献

1
Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis.角质形成细胞中组胺非依赖性瘙痒介质的异常表达可能与结节性痒疹的发病机制有关。
Acta Derm Venereol. 2019 May 1;99(6):579-586. doi: 10.2340/00015555-3150.
2
A systematic review of evidence-based treatments for prurigo nodularis.结节性痒疹的循证治疗系统评价。
J Am Acad Dermatol. 2019 Mar;80(3):756-764. doi: 10.1016/j.jaad.2018.09.020. Epub 2018 Sep 25.
3
Prurigo Nodularis and Its Management.结节性痒疹及其治疗
Dermatol Clin. 2018 Jul;36(3):189-197. doi: 10.1016/j.det.2018.02.003. Epub 2018 Mar 20.
4
Chronic Prurigo of Nodular Type: A Review.结节性痒疹：综述。
Acta Derm Venereol. 2018 Feb 7;98(2):173-179. doi: 10.2340/00015555-2774.
5
European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.欧洲皮肤病学会和性病学会：慢性瘙痒症定义、分类和术语的专家共识。
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1059-1065. doi: 10.1111/jdv.14570. Epub 2017 Sep 22.
6
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).阿普米拉斯、依那西普和安慰剂治疗中重度斑块状银屑病患者的疗效和安全性：一项IIIb期随机安慰剂对照试验（LIBERATE）的52周结果
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19.
7
Anxiety, depression and suicide in patients with prurigo nodularis.结节性痒疹患者的焦虑、抑郁与自杀
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e106-e107. doi: 10.1111/jdv.13827. Epub 2016 Aug 9.
8
The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration.结节性痒疹的发病机制——探索“超级瘙痒”
Eur J Pain. 2016 Jan;20(1):37-40. doi: 10.1002/ejp.767. Epub 2015 Sep 28.
9
The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).阿普米司特（一种口服磷酸二酯酶 4 抑制剂）对银屑病关节炎患者循环炎症生物标志物水平的药效学影响：来自 III 期、随机、安慰剂对照试验（PALACE 1）的亚研究结果。
J Immunol Res. 2015;2015:906349. doi: 10.1155/2015/906349. Epub 2015 Apr 20.
10
Interleukin-31: a novel diagnostic marker of allergic diseases.白细胞介素-31：一种过敏性疾病的新型诊断标志物。
Curr Allergy Asthma Rep. 2014 Apr;14(4):423. doi: 10.1007/s11882-014-0423-y.